LIGHT产品信息
英文名称:Tumor necrosis factor superfamily member 14
中文名称:肿瘤坏死因子超家族成员14
靶点别称:CD258 antigen,CD258,HVEM-L,LIGHT,LTg,TNFSF14,TR2,HVEML
物种:Human / Mouse / Cynomolgus
属性:Protein / Kits / Cell
标记:Unconjugated
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
LIGHT分子背景
肿瘤坏死因子配体超家族成员14(LIGHT)是一种肿瘤坏死因子(TNF)超家族配体,通过疱疹病毒进入介体(HVEM)和淋巴毒素β受体(LTbetaR)发出信号来调节T细胞免疫反应。LIGHT已成为影响CTL介导的肿瘤排斥、同种异体排斥和移植物抗宿主病的T细胞共刺激信号的有力发起者。LIGHT的组成性表达导致组织破坏和自身免疫样疾病综合征。
LIGHT用户评价
关键字: LIGHT;LIGHT蛋白;CD258;CD258蛋白;LIGHT抗原;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。